Aim-To investigate the hypothesis that complement mediates the recruitment of mononuclear osteoclast precursors to the exposed mineralised bone surface. Methods-Synthetic hydroxyapatite was incubated in vitro with fresh human serum, with and without complement activation inhibitors. Assays for complement components and the generation of the C3 breakdown product C3d were done. C3 deposition in human fetal tibia primary spongiosa was localised immunohistochemically and complement receptors CR1, CR2, CR3, and CR4 were localised celiularly. Immunohistochemical and enzyme histochemical characterisation of the mononuclear and multinuclear osteoclasts was made with emphasis on their association with complement C3 deposition. Results-Components of complement bind to synthetic hydroxyapatite crystals and, at lower concentrations, C3d was generated in the fluid phase. C3 was deposited in a focal and linear distribution on newly formed bone trabecular surfaces in the primary spongiosa. In a similar distribution CD61, CD68, and tartrate resistant acid phosphatase positive mononuclear osteoclasts were shown in close apposition to the bone trabecular surface. These mononuclear osteoclasts, unlike multinucleate osteoclasts, expressed the complement receptors CR3 and CR4. CR1 and CR2, however, could not be shown on either mononuclear or multinuclear osteoclasts. Conclusion-It is suggested that C3 deposition on mineralised bone surfaces mediates the recruitment of mononuclear osteoclasts to this site. As the mononuclear osteoclasts fuse to form the multinucleate osteoclast, complement receptor expression is lost. (7 Clin Pathol 1993;46:517-521) Osteoclasts are multinucleated cells which resorb bone. Osteoclasts attain their multinucleated form by fusion of mononuclear precursors.' Studies on chick-quail chimera,2 3 parabiotic rats,4 and marrow transplantation in osteopetrotic rats56 show that osteoclast precursors are circulating cells originating in the bone marrow. These precursors have not been identified, although they are believed to belong to the monocyte-macrophage lineage. In support of this, the immunophenotype of osteoclasts has been well characterised and shown to express many of the antigens of the monocyte-macrophage lineage.7 Mononuclear cells have been identified in histological sections of bone. These are closely applied to the bone surface and show a similar immunophenotype to that of the multinucleate osteoclasts.8
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There is evidence to suggest that hydroxyapatite crystals in mineralised bone will bind the third component of the complement system (C3) on exposure to plasma.'2 Our initial studies centre around in vitro experiments to clarify this issue. To assess the role of complement in vivo, frozen tissue sections of human fetal long bones were used. The primary spongiosa provides a dynamic view of bone cellular metabolism in that sequential stages of unidirectional bone growth are represented from the calcifying zone of hypertrophic chondrocytes, through the area of rapid bone deposition coupled to a lesser degree of osteoclasis in the primary spongiosa, to the increasingly quiescent region in the diaphysis. Using immunohistochemical means, linear and focal deposition of C3 was detected on exposed mineralised bone in the primary spongiosa. For C3 to be involved in the recruitment of osteoclast precursors, these cells must express complement receptors. Attention was focused on the expression of complement receptors by multinucleate osteoclasts and their mononuclear precursors. (4) 4 (4) *Mean (SD). Table 3 Serum plus: Nil Zymosan 10 mg/ml HAC 10 mg/mi HAC 100 mg/ml 
, and CD18 (complement receptors for iC3b-also known as CR3 and CR4) (fig 3) . These mononuclear cells did not stain with antibodies against the complement receptors for C3b and C3d-CD35 and CD21 (CR1 and CR2, respectively). Multinucleate osteoclasts did not stain positively for any of the complement receptors. No mononuclear or multinuclear osteoclasts were seen in the bone at a distance away from the ossification front (in the diaphysis).
Immunostaining for C3 showed a focal intense staining distribution along stretches of newly formed bone trabeculae in the primary spongiosa immediately adjacent to the endochondral growth plate (in the same region as most of the TRAP positive mononuclear osteoclasts were found) (fig 4) . Immunostaining was particularly intense in surface areas that clearly lacked an overlying osteoid losely seam (areas where mineralised bone is exposed at the surface). C3 was not demonstrable on the surface of thicker trabeculae of bone at a distance from the growth plate (in the diaphyses).
Discussion
In the past hydroxyapatite has been used in preparative columns for the selective removal of some components of complement including C3.12 In our own experiments we have shown that incubation of serum with hydroxyapatite crystals (HAC) leads to a dose dependent and selective depletion of some components of complement. This was to be expected because it is known that Clq binds to anionic surfaces and that on activation the exposed thiol-ester groups of C3 and C4 form ester linkages with hydroxyl groups. '3 Binding of C lq to HAC has been shown and might be expected to lead to classical pathway activation and binding of activated C3 which would be reinforced by concomitant activation of the alternate pathway. Conven It was in the zone of C3 deposition that we found complement receptor positive mononuclear cells in close apposition to the bone trabecular surface. We were unable to show the presence of CR1 (CD35) or CR2 (CD21) on either the TRAP positive mononuclear cells or the multinucleate osteoclasts. CR1 and CR2 bind complement components C3b and C3d, respectively. The TRAP positive mononuclear cells expressed CR3 and CR4 (CD11b + CD18, and CD11c + CD18, respectively). CR3 and CR4 belong to the /2 family of integrins (as defined by their ,B chain CD 18). Both receptors recognise the ArgGly-Asp (RGD) sequence of iC3b-that is, the cleaved, inactivated, and short-lived surface bound component of C3."3 It seems reasonable to hypothesise that, in the primary spongiosa at the endochondral ossification front, C3 is bound to exposed HACs of newly formed bone, converted to iC3b, C3d,g and C3d, and that mononuclear precursors of osteoclasts are bound to these areas by their complement receptors. Chambers showed that in vitro macrophages fuse by the simultaneous phagocytosis of material and, in so doing, internalise and lose the surface expression of the receptors responsible for the binding of that material.'5 16 In a similar way we suggest that the mononuclear osteoclast precursors are attracted to the mineralised bone surface by binding complement and that subsequent internalisation of complement receptors 3 and 4, accounts for their absence on multinucleate osteoclasts. 
